Clinical applications of tumour necrosis factor

Progress in Growth Factor Research
A L Jones, P Selby

Abstract

Tumour necrosis factor (TNF) is a polypeptide hormone produced in vivo by activated macrophages and lymphocytes. TNF has diverse effects in vivo and has a physiological role as an immune modulator, as a mediator of the immune response, both through activation of neutrophils and eosinophils, and also affects the vascular endothelium. TNF also has antiviral activity and causes alterations in lipid metabolism. In disease states excessive production of TNF may have adverse affects. TNF has been implicated as a mediator of endotoxic shock, inflammatory joint disease, immune deficiency states, allograft rejection, and in the cachexia associated with malignant disease and some parasitic infections. When used in pharmacological doses, TNF is cytotoxic to many malignant cells in vitro and in vivo. The mechanisms underlying cytotoxicity are not fully elucidated but involve both a direct toxic effect to the cell and an indirect effect on tumour vasculature. Cytotoxicity is not universal and TNF may act as a differentiating agent or growth factor for some haematological cell types. So far the clinical application of TNF has been as a treatment for cancer in Phase I and II trials in patients with advanced disease and its efficacy here is st...Continue Reading

References

Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·D CaputA Cerami
Nov 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·J S PattonC Grunfeld
Aug 8, 1987·Lancet·F R Balkwill, J F Smyth
Jun 9, 1988·The New England Journal of Medicine·H R MichieD W Wilmore
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C DollbaumH S Smith
Feb 27, 1988·Lancet·P J SelbyT J McElwain
Mar 16, 1989·Nature·E Y JonesN P Walker
Jan 1, 1989·Cancer Chemotherapy and Pharmacology·P J CreavenA D Proefrock
Jun 25, 1985·Nucleic Acids Research·L FransenA Van Vliet
Sep 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·F C KullP Cuatrecasas
Nov 15, 1986·International Journal of Cancer. Journal International Du Cancer·P G BrouckaertW Fiers
Jun 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·I C KettelhutA L Goldberg
Dec 1, 1987·European Journal of Immunology·M TurnerM Feldmann
Oct 1, 1987·The Journal of Experimental Medicine·C P Maury, A M Teppo
Jan 1, 1987·Cancer Chemotherapy and Pharmacology·K KimuraH Majima
Feb 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L ShermanD W Kufe
Mar 1, 1988·The Journal of Experimental Medicine·K J TraceyA Cerami
Aug 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FeinbergJ U Gutterman
Dec 1, 1987·British Journal of Cancer·P SelbyJ Humphreys
Jan 1, 1987·Ciba Foundation Symposium
Sep 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·D SpriggsD W Kufe

❮ Previous
Next ❯

Citations

Jul 1, 1992·General Pharmacology·Y OztürkV M Altan
Oct 15, 2005·Leukemia·S H Kaufmann, D P Steensma
Jul 1, 1999·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·V M VasandaniR J Youle
Apr 21, 2009·Molecular Ecology·C J ThorogoodS J Hiscock
Jul 16, 2013·Biochemical and Biophysical Research Communications·Bobby L JohnsonCharles C Caldwell
Apr 4, 2006·Drug Discovery Today·David L Simmons
Aug 1, 1993·The British Journal of Surgery·S HillJ M Thomas
Oct 2, 2001·The British Journal of Surgery·A Gupta, D I Watson
May 12, 2004·Surgical Endoscopy·S J Neuhaus, D I Watson
Oct 1, 1996·Immunology and Cell Biology·J A BarbaraA Lopez
Jun 20, 1992·BMJ : British Medical Journal·T Perren, P Selby
Aug 1, 1992·BMJ : British Medical Journal·S Malik, J Waxman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.